DK2066354T3 - Norovirus vaccine formuleringer - Google Patents

Norovirus vaccine formuleringer

Info

Publication number: DK2066354T3
Authority: DK; Denmark
Prior art keywords: vaccine formulations; norovirus vaccine; norovirus; formulations; vaccine
Prior art date: 2006-09-29

Application number

DK07853688.5T

Other languages

English (en)

Inventor

Charles Richardson

Thomas S Vedvick

Thomas R Foubert

William T Tino

Original Assignee

Ligocyte Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-29

Filing date

2007-09-28

Publication date

2013-05-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2066354(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-28 Application filed by Ligocyte Pharmaceuticals Inc filed Critical Ligocyte Pharmaceuticals Inc

2013-05-27 Application granted granted Critical

2013-05-27 Publication of DK2066354T3 publication Critical patent/DK2066354T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

DK07853688.5T 2006-09-29 2007-09-28 Norovirus vaccine formuleringer DK2066354T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US84791206P	2006-09-29	2006-09-29
US97339207P	2007-09-18	2007-09-18
PCT/US2007/079929 WO2008042789A1 (en)	2006-09-29	2007-09-28	Norovirus vaccine formulations

Publications (1)

Publication Number	Publication Date
DK2066354T3 true DK2066354T3 (da)	2013-05-27

Family

ID=39268804

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK13157573.0T DK2601970T3 (da)	2006-09-29	2007-09-28	Norovirus-vaccine-formuleringer
DK13157572.2T DK2601969T3 (da)	2006-09-29	2007-09-28	Norovirus-vaccineformuleringer
DK07853688.5T DK2066354T3 (da)	2006-09-29	2007-09-28	Norovirus vaccine formuleringer

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK13157573.0T DK2601970T3 (da)	2006-09-29	2007-09-28	Norovirus-vaccine-formuleringer
DK13157572.2T DK2601969T3 (da)	2006-09-29	2007-09-28	Norovirus-vaccineformuleringer

Country Status (16)

Country	Link
US (8)	US7955603B2 (da)
EP (4)	EP2641613A1 (da)
JP (3)	JP5476544B2 (da)
KR (1)	KR101515489B1 (da)
AU (1)	AU2007303608B2 (da)
CA (1)	CA2664157C (da)
CY (1)	CY1118492T1 (da)
DK (3)	DK2601970T3 (da)
ES (3)	ES2420136T3 (da)
HU (2)	HUE028978T2 (da)
LT (1)	LT2601970T (da)
PL (2)	PL2601970T3 (da)
PT (1)	PT2601970T (da)
SG (3)	SG10202012986SA (da)
SI (1)	SI2601970T1 (da)
WO (1)	WO2008042789A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2641613A1 (en)	2006-09-29	2013-09-25	Ligocyte Pharmaceuticals, Inc.	Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant
KR20150098681A (ko)	2007-03-14	2015-08-28	다케다 백신즈 인코포레이티드	바이러스 유사 입자 정제
US20100266636A1 (en) *	2007-09-18	2010-10-21	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
CN101918028B (zh)	2007-09-18	2015-01-07	莱戈赛特医药股份有限公司	赋予针对诺如病毒的保护性免疫应答的疫苗
PL2324113T3 (pl) *	2008-08-08	2018-08-31	Takeda Vaccines, Inc.	Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej
WO2010111586A2 (en) *	2009-03-27	2010-09-30	Arizona Board Of Regents Acting For And On Behalf Of Arizona State University	Mucosal immunization
US20110070260A1 (en) *	2009-09-09	2011-03-24	Baric Ralph S	Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
US9439958B2 (en) *	2009-12-23	2016-09-13	Arizona Board Of Regents Acting For And On Behalf Of Arizona State University	Stabilized virus like particles having enhanced mucosal immunogenicity
KR20120125627A (ko)	2010-01-21	2012-11-16	리고사이트 파머슈티컬즈 인코퍼레이티드	칼리시바이러스 바이러스 유사 입자들 상에 표적화된 이종 항원 제공
EP2558120A4 (en) *	2010-04-15	2013-08-28	Shin Nippon Biomedical Lab Ltd	METHOD AND COMPOSITION FOR INTRANASAL ADMINISTRATION
AU2012244074B2 (en) *	2010-04-15	2015-01-15	Km Biologics Co., Ltd.	Methods and compositions for intranasal delivery
EA202090699A3 (ru) *	2011-07-11	2020-11-30	Такеда Вэксинс, Инк.	Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
JOP20130186B1 (ar) *	2012-06-22	2021-08-17	Takeda Vaccines Montana Inc	تنقية الجزيئات الشبيهة بالفيروسات
US20140017257A1 (en) *	2012-07-11	2014-01-16	Xi Jiang	IgY From Norovirus P Particles And Their Derivatives
EP3421997B1 (en) *	2012-12-28	2020-06-17	Cellestis Limited	A cell mediated immune response assay
US9975923B2 (en)	2013-03-15	2018-05-22	The University Of North Carolina At Chapel Hill	Methods and compositions for norovirus blockade epitopes
WO2014145245A2 (en) *	2013-03-15	2014-09-18	The University Of North Carolina At Chapel Hill	Methods and compositions for norovirus blockade epitopes
JP6479305B2 (ja)	2013-07-12	2019-03-06	株式会社Ｕｍｎファーマ	ウイルス様粒子の精製方法
JP2015015931A (ja)	2013-07-12	2015-01-29	株式会社Ｕｍｎファーマ	ウイルス様粒子を含む培養物の製造方法
JP2015017065A (ja) *	2013-07-12	2015-01-29	株式会社Ｕｍｎファーマ	ノロウイルスのウイルス様粒子を含む医薬組成物
EP3021871A1 (en)	2013-07-17	2016-05-25	Dow Global Technologies LLC	Composition for application to a mucosa comprising a methylcellulose
KR102474663B1 (ko)	2013-10-03	2022-12-07	다케다 백신즈 인코포레이티드	세포주로부터 랍도바이러스를 탐지 및 제거하는 방법
EP3085357B1 (en) *	2013-12-16	2019-02-13	Takeda Pharmaceutical Company Limited	Microneedle
JP7033534B2 (ja) *	2015-08-28	2022-03-10	オロジーバイオサーヴィシズ、インク．	ノロウイルスワクチン
KR101914779B1 (ko) *	2016-03-18	2018-11-02	(주)인테라	노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
CN107184970A (zh) *	2017-02-16	2017-09-22	北京生物制品研究所有限责任公司	口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
EP3600397A4 (en)	2017-03-28	2021-01-27	Children's Hospital Medical Center	NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES
PH12020550732A1 (en)	2017-11-30	2021-04-19	Medicago Inc	Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
US11633467B2 (en)	2018-02-15	2023-04-25	Icon Genetics Gmbh	Immunogenic composition and vaccine for generating an immune response to norovirus
JP6713013B2 (ja) *	2018-03-06	2020-06-24	株式会社イーダブルニュートリション・ジャパン	貝類のノロウイルス不活化方法
CA3106471A1 (en)	2018-07-13	2020-01-16	Medicago Inc.	Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
US20210308249A1 (en)	2018-08-20	2021-10-07	Takeda Vaccines, Inc.	Vlp formulations
JP2022502482A (ja) *	2018-09-17	2022-01-11	ボードオブリージェンツザユニヴァーシティオブテキサスシステム	骨損傷を治療するための組成物及び方法
US11523988B2 (en)	2018-11-29	2022-12-13	Catalent U.K. Swindon Zydis Limited	Oral dispersible vaccine comprising virosomes
EP3698773A1 (en)	2019-02-21	2020-08-26	Università degli Studi di Parma	Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
KR20220021451A (ko)	2019-03-12	2022-02-22	아이콘 제네틱스 지엠비에이치	안정성이 향상된 노로바이러스 유사 입자
CN115023219A (zh) *	2019-08-13	2022-09-06	艾尔特免疫公司	治疗剂的有效性及其施用途径
EP4165205A1 (en) *	2020-06-15	2023-04-19	CureVac SE	Analysis of nucleic acid mixtures
JP2024519800A (ja)	2021-05-21	2024-05-21	タケダワクチン，インコーポレイテッド	固体組成物、フリーズドライ方法およびガラスバイアル
US20250197454A1 (en)	2022-03-18	2025-06-19	Denka Company Limited	Virus-like particle containing capsid proteins connected by linker
WO2025076792A1 (en) *	2023-10-12	2025-04-17	Chengdu Kanghua Biological Product Co., Ltd.	Methods of preparing norovirus vaccine with low amounts of adjuvant
CN117330750A (zh) *	2023-12-01	2024-01-02	北京生物制品研究所有限责任公司	一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6572862B1 (en)	1989-11-08	2003-06-03	Baylor College Of Medicine	Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) *	1991-03-25	1992-10-21	Board Of Trustees Of The Leland Stanford Junior University	Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
CA2133339A1 (en)	1992-04-08	1993-10-09	Jennifer S. Rota	Wild-type measles virus glycoproteins: vaccine and detection method therefor
ATE204762T1 (de)	1993-03-23	2001-09-15	Smithkline Beecham Biolog	3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5788970A (en)	1994-03-29	1998-08-04	The University Of Maryland College Park	Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
BR9507657A (pt)	1994-05-16	1997-09-09	Merck & Co Inc	Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
US5645051A (en) *	1995-04-21	1997-07-08	Dura Pharmaceuticals, Inc.	Unit dose dry powder inhaler
US5861241A (en) *	1995-08-16	1999-01-19	University Of Massachusetts	Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) *	1995-12-07	1996-02-07	Danbiosyst Uk	Vaccine compositions
US5834015A (en)	1996-09-11	1998-11-10	Albany Medical College	Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en)	1996-10-10	1999-09-14	Incyte Pharmaceuticals, Inc.	Project-based full-length biomolecular sequence database
US6491919B2 (en) *	1997-04-01	2002-12-10	Corixa Corporation	Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
ATE261734T1 (de)	1997-04-08	2004-04-15	Merck & Co Inc	Stabilisierte humane papillomaviruszusammensetzungen
CA2288129A1 (en)	1997-05-01	1998-11-12	Chiron Corporation	Use of virus-like particles as adjuvants
US20040265377A1 (en)	1997-10-27	2004-12-30	Harry Seager	Solid dispersing vaccine composition for oral delivery
HRP20010113A2 (en)	1998-08-14	2002-02-28	Merck & Co Inc	Process for purifying human papillomavirus virus-like particles
DE69930960T2 (de)	1998-12-17	2007-04-19	Merck & Co., Inc.	Synthetische virus-ähnliche partikel mit heterologen epitopen.
JP4841726B2 (ja)	1999-02-05	2011-12-21	メルク・シャープ・エンド・ドーム・コーポレイション	ヒトパピローマウイルスワクチン製剤
AU768992B2 (en)	1999-06-22	2004-01-15	Denka Seiken Co., Ltd.	SRSV detection kit
US20040121465A1 (en)	2002-02-14	2004-06-24	Novavax, Inc.	Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206359D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
US7135180B2 (en)	2002-04-11	2006-11-14	Medimmune Vaccines, Inc.	Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en)	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
CA2486118A1 (en)	2002-06-07	2003-12-18	Large Scale Biology Corporation	Flexible vaccine assembly and vaccine delivery platform
WO2004000351A1 (en)	2002-06-20	2003-12-31	Cytos Biotechnology Ag	Packaged virus-like particles for use as adjuvants: method of preparation and use
DE602004020189D1 (de)	2003-01-30	2009-05-07	Novartis Vaccines & Diagnostic	Adjuvante influenza-vakzine
US20040213745A1 (en)	2003-02-20	2004-10-28	Vincent Sullivan	Powder formulations of rSEB for improved vaccination
US8592197B2 (en)	2003-07-11	2013-11-26	Novavax, Inc.	Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en)	2003-07-21	2005-04-14	Boyce Thompson Institute For Plant Research, Inc.	Vectors and methods for immunization against norwalk virus using transgenic plants
WO2005030806A2 (en)	2003-09-24	2005-04-07	Montana State University	Norovirus monoclonal antibodies and peptides
US7795242B2 (en)	2003-10-15	2010-09-14	The Brigham And Women's Hospital, Inc.	Methods and compositions for immunomodulation
US20050215501A1 (en)	2003-10-24	2005-09-29	Coley Pharmaceutical Group, Inc.	Methods and products for enhancing epitope spreading
FR2863890B1 (fr)	2003-12-19	2006-03-24	Aventis Pasteur	Composition immunostimulante
US7481997B1 (en) *	2004-02-12	2009-01-27	Montana State University	Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en)	2004-05-18	2005-11-24	Goldberg Joanna B	Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es)	2004-09-03	2010-02-23	Ct Ingenieria Genetica Biotech	Composición vacunal contra el virus de la hepatitis c
AU2005295438B2 (en)	2004-10-20	2012-07-05	Sanofi Pasteur Biologics, Llc	Vaccines against Japanese encephalitis virus and West Nile virus
GB0428394D0 (en)	2004-12-24	2005-02-02	Chiron Srl	Saccharide conjugate vaccines
WO2006074303A2 (en)	2005-01-05	2006-07-13	Philadelphia Health And Education Corporation	Delivery vehicles, bioactive substances and viral vaccines
US8168771B2 (en)	2005-01-31	2012-05-01	The Johns Hopkins University	Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
ATE552267T1 (de)	2005-02-18	2012-04-15	Novartis Vaccines & Diagnostic	Immungene von uropathogenen escherichia coli
WO2006097530A2 (en)	2005-03-18	2006-09-21	Cytos Biotechnology Ag	Cat allergen fusion proteins and uses thereof
CN101287489A (zh)	2005-06-01	2008-10-15	陶氏环球技术公司	多价病毒样颗粒的生产
EP1736538A1 (en)	2005-06-21	2006-12-27	Cytos Biotechnology AG	Process for the preparative purification of virus-like-particles (VLPs)
EP2360175B1 (en)	2005-11-22	2014-07-16	Novartis Vaccines and Diagnostics, Inc.	Norovirus and Sapovirus virus-like particles (VLPs)
JP2007145775A (ja)	2005-11-29	2007-06-14	Falco Life Science:Kk	ノロウイルスｇｉの高感度検出方法
EP2641613A1 (en)	2006-09-29	2013-09-25	Ligocyte Pharmaceuticals, Inc.	Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant
ES2480491T3 (es)	2006-12-06	2014-07-28	Novartis Ag	Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
US8474614B2 (en) *	2007-03-14	2013-07-02	BBY Solutions	Protective container for a flat screen monitor
KR20150098681A (ko)	2007-03-14	2015-08-28	다케다 백신즈 인코포레이티드	바이러스 유사 입자 정제
CN101918028B (zh) *	2007-09-18	2015-01-07	莱戈赛特医药股份有限公司	赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en)	2007-09-18	2010-10-21	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
PL2324113T3 (pl)	2008-08-08	2018-08-31	Takeda Vaccines, Inc.	Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej
AU2009338516A1 (en)	2009-01-22	2011-08-18	Pharmathene, Inc.	Stable vaccine compositions and methods of use
EP2942062A1 (en)	2009-02-10	2015-11-11	Novartis AG	Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en)	2009-09-09	2011-03-24	Baric Ralph S	Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
KR20120125627A (ko)	2010-01-21	2012-11-16	리고사이트 파머슈티컬즈 인코퍼레이티드	칼리시바이러스 바이러스 유사 입자들 상에 표적화된 이종 항원 제공
JP6324067B2 (ja)	2010-05-26	2018-05-16	セレクタバイオサイエンシーズインコーポレーテッドＳｅｌｅｃｔａＢｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ．	多価合成ナノキャリアワクチン
EA202090699A3 (ru)	2011-07-11	2020-11-30	Такеда Вэксинс, Инк.	Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
JOP20130186B1 (ar)	2012-06-22	2021-08-17	Takeda Vaccines Montana Inc	تنقية الجزيئات الشبيهة بالفيروسات

2007
- 2007-09-28 EP EP13173005.3A patent/EP2641613A1/en not_active Withdrawn
- 2007-09-28 SG SG10202012986SA patent/SG10202012986SA/en unknown
- 2007-09-28 DK DK13157573.0T patent/DK2601970T3/da active
- 2007-09-28 DK DK13157572.2T patent/DK2601969T3/da active
- 2007-09-28 ES ES07853688T patent/ES2420136T3/es active Active
- 2007-09-28 LT LTEP13157573.0T patent/LT2601970T/lt unknown
- 2007-09-28 PL PL13157573T patent/PL2601970T3/pl unknown
- 2007-09-28 JP JP2009530639A patent/JP5476544B2/ja active Active
- 2007-09-28 CA CA2664157A patent/CA2664157C/en active Active
- 2007-09-28 ES ES13157573.0T patent/ES2618885T3/es active Active
- 2007-09-28 EP EP07853688.5A patent/EP2066354B1/en active Active
- 2007-09-28 SG SG10201502490YA patent/SG10201502490YA/en unknown
- 2007-09-28 KR KR1020097008725A patent/KR101515489B1/ko active Active
- 2007-09-28 HU HUE13157572A patent/HUE028978T2/en unknown
- 2007-09-28 HU HUE13157573A patent/HUE032422T2/en unknown
- 2007-09-28 PL PL13157572.2T patent/PL2601969T3/pl unknown
- 2007-09-28 EP EP13157573.0A patent/EP2601970B1/en not_active Revoked
- 2007-09-28 WO PCT/US2007/079929 patent/WO2008042789A1/en not_active Ceased
- 2007-09-28 SG SG2011071123A patent/SG174845A1/en unknown
- 2007-09-28 EP EP13157572.2A patent/EP2601969B1/en active Active
- 2007-09-28 SI SI200731885A patent/SI2601970T1/sl unknown
- 2007-09-28 AU AU2007303608A patent/AU2007303608B2/en active Active
- 2007-09-28 ES ES13157572.2T patent/ES2577833T3/es active Active
- 2007-09-28 DK DK07853688.5T patent/DK2066354T3/da active
- 2007-09-28 PT PT131575730T patent/PT2601970T/pt unknown
- 2007-09-28 US US12/093,921 patent/US7955603B2/en active Active
2010
- 2010-06-16 US US12/816,495 patent/US8431116B2/en active Active
2011
- 2011-12-20 US US13/330,854 patent/US20120093861A1/en not_active Abandoned
2013
- 2013-03-15 US US13/836,446 patent/US10010599B2/en active Active
- 2013-03-15 US US13/837,653 patent/US9308249B2/en active Active
- 2013-03-15 US US13/837,885 patent/US9272028B2/en active Active
- 2013-06-24 JP JP2013131559A patent/JP5898133B2/ja active Active
2015
- 2015-07-10 US US14/796,714 patent/US9861691B2/en active Active
- 2015-10-05 JP JP2015197633A patent/JP6134364B2/ja active Active
2017
- 2017-01-25 CY CY20171100109T patent/CY1118492T1/el unknown
2018
- 2018-05-31 US US15/994,887 patent/US10512682B2/en active Active

Also Published As

Publication number	Publication date
EP2601969A2 (en)	2013-06-12
EP2601970B1 (en)	2016-10-26
US20130273105A1 (en)	2013-10-17
EP2601970A1 (en)	2013-06-12
US20120093861A1 (en)	2012-04-19
AU2007303608A1 (en)	2008-04-10
AU2007303608B2 (en)	2013-05-02
EP2601969A3 (en)	2013-08-21
ES2618885T3 (es)	2017-06-22
HK1184057A1 (en)	2014-01-17
US20080299152A1 (en)	2008-12-04
US9308249B2 (en)	2016-04-12
CA2664157A1 (en)	2008-04-10
PL2601969T3 (pl)	2016-10-31
JP2013234188A (ja)	2013-11-21
US10512682B2 (en)	2019-12-24
HUE028978T2 (en)	2017-02-28
SG10202012986SA (en)	2021-01-28
JP5476544B2 (ja)	2014-04-23
US9272028B2 (en)	2016-03-01
SG10201502490YA (en)	2015-05-28
PT2601970T (pt)	2017-02-02
US7955603B2 (en)	2011-06-07
HUE032422T2 (en)	2017-09-28
US10010599B2 (en)	2018-07-03
US20140286994A1 (en)	2014-09-25
US20120156243A1 (en)	2012-06-21
DK2601970T3 (da)	2017-02-06
US9861691B2 (en)	2018-01-09
EP2641613A1 (en)	2013-09-25
US8431116B2 (en)	2013-04-30
KR20090079912A (ko)	2009-07-22
EP2601969B1 (en)	2016-03-30
JP2010505766A (ja)	2010-02-25
ES2577833T3 (es)	2016-07-19
EP2066354A1 (en)	2009-06-10
CA2664157C (en)	2015-12-01
CY1118492T1 (el)	2017-07-12
EP2066354A4 (en)	2010-10-20
WO2008042789A1 (en)	2008-04-10
US20190125853A1 (en)	2019-05-02
US20160008455A1 (en)	2016-01-14
EP2066354B1 (en)	2013-04-17
JP2016020378A (ja)	2016-02-04
LT2601970T (lt)	2017-04-25
JP5898133B2 (ja)	2016-04-06
PL2601970T3 (pl)	2017-07-31
KR101515489B1 (ko)	2015-04-30
SG174845A1 (en)	2011-10-28
ES2420136T3 (es)	2013-08-22
US20130273148A1 (en)	2013-10-17
DK2601969T3 (da)	2016-04-18
JP6134364B2 (ja)	2017-05-24
SI2601970T1 (sl)	2017-04-26

Publication	Publication Date	Title
DK2066354T3 (da)	2013-05-27	Norovirus vaccine formuleringer
ATE450271T1 (de)	2009-12-15	Impfstoff
DK2068886T3 (da)	2013-11-18	Lipidholdige præparater
DK1968631T3 (da)	2015-06-15	Vaccine
BRPI0814252A2 (pt)	2015-04-14	Formulações de anticorpo
PT2889310T (pt)	2018-03-26	Formulações de anticorpo
BRPI0820381A2 (pt)	2015-05-19	Formulações farmacêuticas
BRPI0908785A2 (pt)	2015-07-28	Formulações herbicida
DK2114993T3 (da)	2012-10-22	Vaccine
BRPI0814188A2 (pt)	2014-10-14	Formulações
EP2098065A4 (en)	2012-04-04	SWARM PICTURE
DK2200646T3 (da)	2013-10-21	RNA-Vacciner
DE602006021235D1 (de)	2011-05-19	Kristallglasgegenstand
BRPI0814314A2 (pt)	2015-05-26	Microbiocidas
CR10571A (es)	2009-05-14	Vacuna virica recombinante
BRPI0917205A2 (pt)	2015-11-10	vacina polivalente
DE602007001937D1 (de)	2009-09-24	Optischer Tomograph
DK2125048T3 (da)	2014-10-13	Præparat
DK2422810T3 (da)	2014-11-24	Influenzavaccine
BRPI0813781A2 (pt)	2019-09-24	microbiocidas
BRPI0809653A2 (pt)	2014-10-07	Formulações líquidas de manoproteína
EP2061502A4 (en)	2010-10-20	CARBOHYDRATE-BASED VACCINES FOR HLV
EP2016414A4 (en)	2009-08-12	T-cell vaccine
BRPI0810835A2 (pt)	2015-06-16	Formulações de hidroquinona ansamicina
ATE454037T1 (de)	2010-01-15	Haltesystem